Here are 1-2 brief analogies for Enovis (ENOV):

• Enovis is like Stryker or Zimmer Biomet for comprehensive orthopedic solutions, from braces to joint replacements.
• Enovis is like Johnson & Johnson's DePuy Synthes, but as an independent, focused orthopedic company.

• Orthopedic Bracing & Supports: Products designed for injury prevention, recovery, and rehabilitation of joints and soft tissues, including brands like DonJoy and Aircast.
• Surgical Reconstruction Products: Implants and instrumentation used for joint replacement surgeries, particularly in the shoulder, elbow, and ankle.
• Surgical Soft Tissue & Extremity Products: Solutions for arthroscopic procedures, soft tissue repair, and internal fixation for injuries in the hand, wrist, foot, and ankle.
• Vascular & Pain Therapy Devices: Medical devices focused on deep vein thrombosis (DVT) prevention and electrotherapy for pain management and recovery.

Damien McDonald, Chief Executive Officer

Damien McDonald joined Enovis as CEO on May 12, 2025, bringing over 35 years of experience in the medical device industry. Prior to Enovis, he served as CEO of LivaNova, a global business focused on medical devices, where he improved growth, profitability, and shareholder value. His career also includes leadership roles at MedTech, including Group Executive and Corporate Vice President for dental consumables companies at Danaher, leading Zimmer's spine division, and spearheading global marketing for Johnson & Johnson's Ethicon business unit.

Ben Berry, Chief Financial Officer

Ben Berry has served as Chief Financial Officer and Senior Vice President of Enovis since January 2023, having joined the company in 2020. He has demonstrated strong financial leadership throughout his career in the medical technology sector. Before joining Enovis, Mr. Berry spent 18 years at Alcon, where he held finance leadership roles with increasing responsibility in strategy, operations, and business process improvement, including during Alcon's launch as an independent public company. At Enovis, he has been instrumental in strengthening financial teams and processes, contributing to improved operating performance and profit margins, and playing a key role in the company's growth strategy, including acquisitions.

Brady R. Shirley, Executive Advisor and Director

Brady Shirley has served as a director of Enovis since April 1, 2025, following his retirement as President and Chief Operating Officer of Enovis in April 2024, and now serves as an Executive Advisor. He previously served as Chief Executive Officer of DJO Global. Mr. Shirley joined DJO in 2014 as President of the DJO Surgical business and was appointed CEO in 2016, leading the transaction into Colfax (now Enovis) in 2019. From 2009 to 2013, he was CEO and a Director of Innovative Medical Device Solutions (IMDS), where he oversaw the integration of four companies, consolidated the capital structure, and led a successful sale of the business in 2013. His earlier career includes various leadership positions at Stryker Corporation from 1992 to 2009.

Patricia Lang, Senior Vice President and Chief Human Resources Officer

Patricia Lang serves as the Senior Vice President and Chief Human Resources Officer for Enovis, a role she has held since 2019.

Bradley J. Tandy, Senior Vice President and Chief Legal Officer

Bradley J. Tandy is the Senior Vice President and Chief Legal Officer at Enovis, having assumed this role in 2019. Prior to joining Enovis, he held the position of Executive Vice President, General Counsel, and Secretary at DJO Global.

Enovis (NYSE: ENOV) operates in the medical technology sector, focusing on orthopedic solutions across two main segments: Reconstructive and Prevention & Recovery. The addressable markets for their main products and services are substantial, with various segments exhibiting significant global and regional market sizes.

Reconstructive Segment

This segment includes orthopedic implants for hip, knee, shoulder, elbow, foot, ankle, and finger, along with surgical productivity solutions.

• Hip and Knee Reconstruction: The global market for hip and knee reconstruction is estimated at USD 23.88 billion in 2025 and is projected to grow to USD 41.07 billion by 2035.
• Trauma and Extremities Devices (including foot, ankle, hand, wrist, and elbow implants): The global market size for trauma and extremities devices was valued at USD 14.17 billion in 2023 and is projected to reach USD 24.90 billion by 2034. North America held a significant share of this market, accounting for 46.2% in 2023. Separately, the global extremity products market size was over USD 12.73 billion in 2024 and is poised to exceed USD 29.22 billion by 2037, with North America expected to hold the largest revenue share of 46% by 2037.
• Upper Extremity Reconstruction (specifically shoulder, elbow, hand, and wrist): The global market is estimated at USD 6.5 billion in 2025 and is projected to reach approximately USD 11.5 billion by 2033. North America is poised to dominate this market.
• Shoulder Reconstruction Devices: The global shoulder reconstruction device market was valued at over USD 2.1 billion in 2024 and is expected to increase to over USD 3.4 billion by 2031. The broader shoulder replacement market size is estimated at USD 2.24 billion in 2025 and is expected to reach USD 3.12 billion by 2030, with North America leading with a 39.81% share in 2024.

Prevention & Recovery Segment

This segment encompasses products such as rigid bracing, orthopedic soft goods, vascular systems, compression garments, hot and cold therapy products, bone growth stimulators, and electrical stimulators.

• Orthopedic Braces and Supports: The global orthopedic braces and supports market, which includes various types of braces and supports for the knee, ankle, foot, back, hip, spine, shoulder, elbow, hand, wrist, and face, was valued at US$4.0 billion in 2025 and is projected to reach US$5.5 billion by 2030. Another estimate places the global orthopedic braces and supports market size at USD 4.67 billion in 2024, projected to reach USD 7.006 billion by 2030. North America held the largest market share in this segment in 2024, with a revenue share of 35.83%.

Enovis (ENOV) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

1. Product Innovation and New Product Launches: Enovis is consistently investing in research and development to bring new and advanced medical technologies to market. This includes ongoing product innovations aimed at addressing unmet clinical needs and improving patient outcomes. Examples include the successful launch and planned broader expansion of the ARVIS Ultra system in Q1 and Q2 of 2026, as well as the traction gained by the Augmented Reverse Glenoid System (ARG) and other products in the pipeline.

2. Strategic Acquisitions and Integration: Acquisitions are a significant part of Enovis's growth strategy, allowing the company to expand its product portfolio, market reach, and access to new technologies. The successful integration of recent acquisitions, such as Lima, has been a key catalyst for growth, particularly in international sales, by leveraging cross-selling synergies across various anatomies.

3. International Market Expansion: Enovis is focused on expanding its global footprint to tap into new customer bases and diversify revenue streams. International sales, particularly in the Recon segment, have shown strong growth, driven by strategic initiatives and the integration of acquired businesses like Lima. The company's global presence across North America, Europe, Asia Pacific, and other regions supports this expansion.

4. Organic Growth in the Reconstructive (Recon) Segment: The Reconstructive segment is a significant driver of organic growth for Enovis, with consistent high single-digit growth. This growth is fueled by strong performance in various anatomies, including hips, knees, and extremities, and is expected to continue to outpace the market rate.

5. Operational Excellence and Productivity Improvements: Enovis emphasizes operational efficiency and cost management, which contribute to improved adjusted gross margins and EBITDA. These productivity improvements in manufacturing and supply chain operations, along with a favorable product mix, bolster the company's financial health and provide resources for continued investment in growth initiatives.

Share Issuance

• Enovis expected to issue approximately €100 million in common stock as part of the €800 million acquisition of Lima Corporate S.p.A., which was announced in September 2023 and expected to close in early 2024.
• The company underwent a one-for-three reverse stock split immediately following the separation of ESAB Corporation in April 2022.

Outbound Investments

• Enovis entered into a definitive agreement to acquire Lima Corporate S.p.A., a global orthopedic leader, for €800 million (approximately $860 million) in September 2023, with the transaction expected to close in early 2024.
• In October 2025, Enovis completed the sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million, consisting of an upfront cash payment of $45 million and up to an additional $15 million contingent on future performance.
• The company completed seven small acquisitions in the first and second quarters of 2025, including a distributor, intellectual property, and Prevention & Recovery businesses, totaling $35 million in consideration.

Capital Expenditures

• Cash flows used in investing activities for capital expenditures were $122.2 million in 2023.
• Capital expenditures totaled $105.5 million in 2022.
• In 2021, capital expenditures amounted to $104.2 million.